Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

2.140 -0.170 (-7.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cns Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Scientists Create Open-Source Platform to Analyze Brain Tumors in Kids
Via Investor Brand Network
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NASDAQ:RAIN),(NASDAQ:CNSP),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Study Shows Brain Cancer Among Top Cancer Types in US
Via Investor Brand Network
Researchers Find New Way to Detect Brain Tumors Using Urine Tests
Via Investor Brand Network
CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Proton Beam Therapy Could Boost Quality of Life for Cancer Patients
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves 50%+ Enrollment in Potentially Pivotal Berubicin Study
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Via ACCESSWIRE
Notable Advancements Made in Research, Treatment of Brain Cancer
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2023 Results, Corporate Update
Via Investor Brand Network
New Gel Cures Brain Tumors in Mice
Via Investor Brand Network
Study Finds Possible Pathway to Prevent Brain Cancer Metastasis
Via Investor Brand Network
Researchers Use Genome Sequencing to Determine Genes That Trigger Familial Glioma
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Board Appointment of Pharma and Biotech Industry Veteran Dr. Bettina M. Cockroft
Via Investor Brand Network
Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors
Via ACCESSWIRE
CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study
Via ACCESSWIRE
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Near the Top of Equities by Percentage Gain on 4/20
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Retains Analytics Firm, Investigates Possible Naked Short Selling
Via Investor Brand Network
Topics Law Enforcement
Exposures Legal
CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate, Present at Upcoming Virtual Investor Spotlight Event
Via Investor Brand Network
Study Finds Traditional Chinese Medicine May Create New Way to Treat Brain Cancer
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Potentially Pivotal Berubicin Trial
Via Investor Brand Network
Mechanical Nanosurgery Could Revolutionize Brain Cancer Treatment
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer
Via Investor Brand Network
Study Explores Effects of MRI Scans During Cancer Treatment
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls Over 100 Patients in Potentially Pivotal Berubicin Study
Via Investor Brand Network
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Adds Italy to Growing Portfolio of Countries for Berubicin Study
Via Investor Brand Network
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.